High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Over the years, the relationship between high-density lipoprotein (HDL) and atherosclerosis, initially highlighted by the Framingham study, has been revealed to be extremely complex, due to the multiple HDL functions involved in atheroprotection. Among them, HDL cholesterol efflux capacity (CEC), the ability of HDL to promote cell cholesterol efflux from cells, has emerged as a better predictor of cardiovascular (CV) risk compared to merely plasma HDL-cholesterol (HDL-C) levels. HDL CEC is impaired in many genetic and pathological conditions associated to high CV risk such as dyslipidemia, chronic kidney disease, diabetes, inflammatory and autoimmune diseases, endocrine disorders, etc. The present review describes the current knowledge on HDL CEC modifications in these conditions, focusing on the most recent human studies and on genetic and pathophysiologic aspects. In addition, the most relevant strategies possibly modulating HDL CEC, including lifestyle modifications, as well as nutraceutical and pharmacological interventions, will be discussed. The objective of this review is to help understanding whether, from the current evidence, HDL CEC may be considered as a valid biomarker of CV risk and a potential pharmacological target for novel therapeutic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Estruch, R., Ros, E., Salas-Salvadó, J., Covas, M.-I., Corella, D., Arós, F., Gómez-Gracia, E., Ruiz-Gutiérrez, V., Fiol, M., Lapetra, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800389 · Cited by 3,616 · cited 1×
“A strong consensus indicates that the Mediterranean diet brings significant CV health benefits, as clearly demonstrated by the results of the randomized controlled PREDIMED trial [221].”
BackgroundHigh-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139 · cited 1×
“Nevertheless, clinical studies have failed in proving their capacity to reduce CV risk [23].”
BackgroundLong-term mortality after gastric bypass surgery
Adams, T. D., Gress, R. E., Smith, S. C., Halverson, R. C., Simper, S. C., Rosamond, W. D., LaMonte, M. J., Stroup, A. M., & Hunt, S. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066603 · Cited by 2,572 · cited 1×
“In those patients, bariatric surgery, able to facilitate a substantial weights loss, which has been demonstrated to decrease mortality from CVD [131], further reduced TG and LDL-C levels but also the apoB/apoA-I ratio, Serum Amyloid A (SAA)/PON1 ratio, and increased HDL-C levels, but had no effect on CEC [132].”
BackgroundEffects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022 · cited 1×
“Trials involving treatment with niacin or dalcetrapib failed to demonstrate clinical benefit despite increases in HDL-C [4,52].”
BackgroundCholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943 · cited 3×
“The relevance of the HDL cholesterol efflux promoting function in atheroprotection was highlighted for the first time by Khera and colleagues in 2011 [37].”
BackgroundAssmann, G., Cullen, P., & Schulte, H. (2002) · Circulation · doi:10.1161/hc0302.102575 · Cited by 1,541 · cited 1×
“It is now well established from large-scale epidemiologic studies that HDL represent the main atheroprotective plasma lipid component; indeed, a 1 mg/dl increase in plasma HDL-C is associated with a 3–4% reduction in CV mortality [51].”
HDL cholesterol efflux capacity and incident cardiovascular events
Rohatgi, A., Khera, A., Berry, J. D., Givens, E. G., Ayers, C. R., Wedin, K. E., Neeland, I. J., Yuhanna, I. S., Rader, D. R., de Lemos, J. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409065 · Cited by 1,390 · cited 3×
“In support of the disconnection between CEC and HDL-C levels, an independent inverse association between HDL CEC and incident CV events has been shown independently of HDL-C circulating levels [58,59].”
BackgroundResult
Cited by
The HDL proteome watch: compilation of studies leads to new insights on HDL function
Davidson, W. S., Shah, A. S., Sexmith, H., & Gordon, S. M. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.159072 · Cited by 107
Emerging role of HDL in brain cholesterol metabolism and neurodegenerative disorders
Turri, M., Marchi, C., Adorni, M. P., Calabresi, L., & Zimetti, F. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159123 · Cited by 54
Self-citationZuin, M., Cervellati, C., Trentini, A., Passaro, A., Rosta, V., Zimetti, F., & Zuliani, G. (2021) · Diagnostics · doi:10.3390/diagnostics11060984 · Cited by 45
“cardiovascular disease (CVD) may be driven by the biological function of HDL rather than the concentration of its cargo (Cholesterol) [8,9].”
BackgroundSelf-citationPlasma and cerebrospinal fluid cholesterol esterification is hampered in Alzheimer’s disease
Turri, M., Conti, E., Pavanello, C., Gastoldi, F., Palumbo, M., Bernini, F., Aprea, V., Re, F., Barbiroli, A., Emide, D., et al. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01241-6 · Cited by 27
Self-citation
Metadata
- Authors
- Adorni, M. P., Ronda, N., Bernini, F., & Zimetti, F.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2021-03-05
- Volume
- 10
- Issue
- 3
- Pages
- 574
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W3134019637
- Cited by
- 103
- References
- 23
- FWCI
- 12.71
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.